Dermata Reports Editorial Coverage of Tome Skincare After August Launch
Dermata Therapeutics highlighted coverage of its Tome Skincare brand in four publications following the commercial launch of Tome Foundational Treatment on August 25, 2026.
Dermata Therapeutics, Inc. (NASDAQ:DRMA) has highlighted recent coverage of its Tome Skincare brand in Cosmopolitan, Women's Wear Daily, AIR MAIL and Thingtesting. The company said the coverage followed the commercial launch of Tome Foundational Treatment on August 25, 2026.
Women's Wear Daily covered Tome on August 5, 2026, in an article connected with the launch of Tome Foundational Treatment. According to Dermata, the article discussed the brand's once-weekly skincare format and Bioneedle technology, which is derived from a wild-harvested and minimally processed freshwater sponge.
Cosmopolitan included Tome Foundational Treatment in its “Cosmo's Fall Beauty Edit: The 25 Products We're Actually Using This Season,” a selection prepared by the publication's editors for fall 2026.
AIR MAIL featured the product in the September 2026 edition of its “Hot Stuff” column, written by Linda Wells, the founding editor of Allure magazine. The feature discussed Tome's spicule-based approach and included Wells' personal account of using the treatment.
Thingtesting covered Tome in an interview with Kyra Peckaitis, Dermata's Vice President of Marketing. Dermata described the platform as focused on discovering and evaluating emerging brands.
Tome Foundational Treatment is described by Dermata as a once-weekly skin renewal product powered by Bioneedle. The company says the treatment is designed to improve the appearance of skin tone, texture and overall radiance while simplifying existing skincare routines.
Dermata identifies Bioneedle as a technology based on Spongilla lacustris, a wild-harvested freshwater sponge. The company says Tome products are built around its interest in skincare products connected to scientific research and natural ingredients.
Dermata said the media coverage forms part of its work to establish Tome in the consumer skincare market, build awareness and develop its direct-to-consumer and professional skincare businesses.
In October 2026, the company announced positive topline results from a cosmetic clinical study of Tome Foundational Treatment. Dermata said the study showed improvements across multiple measures of skin appearance and provided additional clinical support for its “Studied Skincare” positioning.
Dermata said it expects to launch Tome Clearing Treatment for acne in the first half of 2027. The company cautioned that the timing and success of planned launches, market acceptance and other commercial outcomes are subject to risks and uncertainties.
Dermata said the articles are independent editorial content and that the views expressed belong to their respective authors. It also stated that personal experiences described in the coverage are individual accounts and do not establish typical or expected results from using Tome products.
Dermata Therapeutics highlighted recent editorial coverage of its Tome Skincare brand following the commercial launch of Tome Foundational Treatment. The coverage appeared in Cosmopolitan, Women's Wear Daily, AIR MAIL and Thingtesting.
Dermata Therapeutics said Tome Foundational Treatment was commercially launched on August 25, 2026. The product is described as the company's first commercial product and is now available at Tome.
Dermata Therapeutics said Tome Skincare has been featured in Cosmopolitan, Women's Wear Daily, AIR MAIL and Thingtesting. The articles are third-party editorial content, and the views and opinions expressed are those of the respective authors rather than Dermata.
Women's Wear Daily ran an exclusive on August 5, 2026, helping announce the launch of Tome Foundational Treatment. Dermata said the article introduced the brand's once-weekly skincare approach and its use of Bioneedle technology, developed from a wild-harvested and minimally processed freshwater sponge.
Cosmopolitan included Tome Foundational Treatment in its “Cosmo's Fall Beauty Edit: The 25 Products We're Actually Using This Season”. The feature was described as a selection of products chosen by the publication's editors for fall 2026.
AIR MAIL featured Tome Foundational Treatment in its September 2026 edition in the “Hot Stuff” column written by Linda Wells, the founding editor of Allure magazine. The article discussed Tome's spicule-based approach and included Ms. Wells' personal experience using the treatment; Dermata said personal experiences do not establish typical or expected results.
Thingtesting featured Tome Skincare in an interview with Kyra Peckaitis, Dermata Therapeutics' Vice President of Marketing. Dermata described Thingtesting as a consumer-focused platform dedicated to discovering and evaluating emerging brands.
Tome Foundational Treatment is described as a once-weekly skin renewal treatment powered by Bioneedle, Dermata Therapeutics' signature ingredient derived from wild-harvested freshwater sponge. The company says it is designed to improve the appearance of skin tone, texture and overall radiance while simplifying existing skincare routines.
Dermata Therapeutics uses Bioneedle in its Tome skincare products. The technology is described as being derived from Spongilla lacustris, a wild-harvested freshwater sponge that is minimally processed.
Dermata Therapeutics is developing direct-to-consumer and professional skincare solutions and said it is working to scale its direct-to-consumer business. The company said its strategy includes establishing Tome in the consumer skincare market, expanding consumer awareness and pursuing additional commercial growth opportunities.
Dermata Therapeutics said it expects to launch Tome Clearing Treatment for acne in the first half of 2027. The statement is forward-looking, and the company cautioned that the timing and success of planned product launches, market acceptance and other commercial outcomes are subject to risks and uncertainties.
Dermata Therapeutics announced positive topline results in October 2026 from a cosmetic clinical study evaluating Tome Foundational Treatment. The company said the study demonstrated improvements across multiple measures of skin appearance and provided additional clinical support for its “Studied Skincare” positioning.
Dermata Therapeutics is identified in the announcement as trading on NASDAQ under the ticker symbol DRMA.